CAPE CANAVERAL, Fla., April 19, 2024 — Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market and to deregister its Class A common stock under Section 12 and Section 12 of the Securities Exchange Act of 1934, as amended , and suspend its reporting obligations under Section 15 of the Exchange Act.
On February 9, 2024, the Company received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Listing Rule 5450 with respect to its Class A common stock, which requires the Company to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, and providing until August 7, 2024 to regain compliance.
On April 19, 2024, the Company notified Nasdaq of its intent to voluntarily delist its Class A common stock from Nasdaq. The Company currently anticipates that it will file with the SEC a Form 25 relating to the delisting and deregistration of its Class A common stock on or about April 29, 2024, and anticipates that the delisting and deregistration under Section 12 of its Class A common stock will then become effective on or about May 9, 2024.
Following the delisting of its Class A common stock from Nasdaq, the Company plans to file with the SEC a Form 15 to deregister its Class A common stock under Section 12 of the Exchange Act and suspend its reporting obligations under Section 15 of the Exchange Act.Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe.